Journal Article

DZNE-2025-00907

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Neurobildgebung mit SPECT und PET in Deutschland: Ergebnisse der 1. Umfrage zur nuklearmedizinischen Neurobildgebung in Deutschland 2023.

Buchert, R. ; Drzezga, A. (First author)DZNE* ; Schreckenberger, M. ; Langen, K. J. ; Meyer, P. T. ; Medicine, W. G. N. N. o. t. G. S. o. N. (Collaboration Author)

2025
Thieme Stuttgart

This record in other databases:  

Please use a persistent id in citations: doi:10.1055/a-2566-1487

Abstract: The advent of disease-modifying therapies for neurodegenerative diseases may result in a growing demand for nuclear neuroimaging procedures presenting opportunities but also challenges to the nuclear medicine community. Whether capacity and expertise in Germany are sufficient to meet an increasing demand for nuclear neuroimaging is under discussion. Against this background, the Neuroimaging Working Group of the German Society of Nuclear Medicine initiated the first survey on the status of nuclear neuroimaging in Germany in 2023. 82 institutions participated in the survey: 33 practices, 15 community hospitals, 34 university hospitals. Primary findings were the following. In practices, brain scans are less frequently performed than in hospitals and are often limited to dopamine transporter SPECT. Brain PET is mainly performed in hospitals, and in community hospitals it is often restricted to FDG PET. Nevertheless, availability of amyloid PET with well-certified quality can be taken for granted. Thus, access to amyloid PET will not be a major bottleneck for new treatments of Alzheimer's disease. Adequate reimbursement and clear anchoring in clinical guidelines have the greatest potential to advance nuclear neuroimaging in Germany. Clinical dopamine transporter SPECT is largely in agreement with procedure guidelines. An area for improvement is the limited availability of MR images to avoid misinterpretation of structural/vascular lesions as nigrostriatal degeneration. The survey provides the first systematic assessment of the status of nuclear neuroimaging in Germany. It underscores the capacity of the German nuclear medicine community to meet an increasing demand for neuroimaging procedures, its adherence to procedure guidelines and identifies topics for improvement.

Keyword(s): Germany (MeSH) ; Humans (MeSH) ; Tomography, Emission-Computed, Single-Photon: statistics & numerical data (MeSH) ; Positron-Emission Tomography: statistics & numerical data (MeSH) ; Neuroimaging: statistics & numerical data (MeSH) ; Neuroimaging: methods (MeSH) ; Surveys and Questionnaires (MeSH) ; Brain: diagnostic imaging (MeSH)

---

Contributing Institute(s):

1. Positron Emissions Tomography (PET) (AG Boecker)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---